Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
19 HKD | 0.00% | -0.11% | -4.33% |
Nov. 24 | Interest Rates, Earnings, FX Roil Asian Stock Markets | MT |
Nov. 23 | Linklogis to Offload Entire 19.6% Stake in Pharma Supply Chain Financing Associate | MT |
Sales 2023 * | 610B 85.16B 665B | Sales 2024 * | 683B 95.41B 745B | Capitalization | 54.17B 7.57B 59.12B |
---|---|---|---|---|---|
Net income 2023 * | 9.06B 1.27B 9.88B | Net income 2024 * | 10.35B 1.45B 11.29B | EV / Sales 2023 * | 0,13x |
Net Debt 2023 * | 22.58B 3.16B 24.64B | Net Debt 2024 * | 1.24B 173M 1.35B | EV / Sales 2024 * | 0,08x |
P/E ratio 2023 * | 5,98x | P/E ratio 2024 * | 5,24x | Employees | 114,766 |
Yield 2023 * | 5,10% | Yield 2024 * | 5,71% | Free-Float | 42.99% |
More Fundamentals
* Assessed data
More news
More recommendations
1 day | -0.11% | ||
1 week | -0.11% | ||
Current month | -2.06% | ||
1 month | -2.27% | ||
3 months | -10.05% | ||
6 months | -28.11% | ||
Current year | -4.33% |
1 week
18.60
19.88

1 month
18.46
20.20

Current year
17.90
28.45

1 year
17.90
28.45

3 years
14.60
28.45

5 years
14.60
36.70

10 years
14.60
45.65

Managers | Title | Age | Since |
---|---|---|---|
Yong Liu
PSD | President | 54 | 2009 |
Shuang Jun Xu
PRN | Corporate Officer/Principal | 54 | 2011 |
Zhong Xi Cai
PRN | Corporate Officer/Principal | 57 | 2010 |
Members of the board | Title | Age | Since |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 51 | 2010 |
Xiao Hui Guan
BRD | Director/Board Member | 52 | 2019 |
Yi Jian Wu
SEC | Corporate Secretary | 53 | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.71% | 9 M€ | -17.23% | ||
3.61% | 2 M€ | +6.24% | - | |
3.52% | 137 M€ | +6.86% | - | |
2.64% | 8 M€ | -17.21% | ||
2.58% | 4 M€ | -27.92% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-06 | 19 | 0.00% | 4 013 893 |
23-12-05 | 19 | +0.21% | 4,095,870 |
23-12-04 | 18.96 | -1.15% | 5,070,637 |
23-12-01 | 19.18 | -1.03% | 2,325,585 |
23-11-30 | 19.38 | +2.00% | 9,345,124 |
Delayed Quote Hong Kong Stock Exchange, December 06, 2023 at 02:45 am EST
More quotes
Sinopharm Group Co Ltd is a China-based company principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-03-21
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy

Mean consensus
BUY
Number of Analysts
14
Last Close Price
17.36CNY
Average target price
25.81CNY
Spread / Average Target
+48.69%
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.33% | 7 583 M $ | |
+22.84% | 61 314 M $ | |
+39.38% | 26 407 M $ | |
-0.79% | 8 194 M $ | |
-14.81% | 4 437 M $ | |
-5.10% | 4 081 M $ | |
+19.02% | 3 965 M $ | |
+36.27% | 3 390 M $ | |
+7.31% | 3 162 M $ | |
+40.48% | 2 717 M $ |